Home > Boards > US Listed > Biotechs > Amarin Corp. PLC ADS (AMRN)

Baabaa45, I shared the warning letter with Amrn

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
ilovetech Member Profile
 
Followed By 6
Posts 783
Boards Moderated 0
Alias Born 02/03/18
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 5/23/2019 5:02:53 PM
Vascepa® to Be Featured in Multiple Scientific Sessions at the National Lipid Association Annual Meeting GlobeNewswire Inc. - 5/16/2019 4:15:00 PM
Quarterly Report (10-q) Edgar (US Regulatory) - 5/1/2019 6:50:57 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 5/1/2019 6:49:35 AM
Amarin Reports First Quarter 2019 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 5/1/2019 5:00:00 AM
New Drug Submission Filed for Vascepa® with Health Canada GlobeNewswire Inc. - 4/29/2019 6:00:00 AM
Proxy Statement (definitive) (def 14a) Edgar (US Regulatory) - 4/25/2019 7:02:14 AM
Amarin To Report First Quarter 2019 Results and Host Conference Call On May 1, 2019 GlobeNewswire Inc. - 4/24/2019 6:00:00 AM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 4/15/2019 5:08:09 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/1/2019 5:09:07 PM
Vascepa® Granted Priority Review Status from Health Canada GlobeNewswire Inc. - 3/29/2019 5:45:15 PM
Amarin Submits Supplemental New Drug Application (sNDA) to U.S. FDA Seeking New Indication for Vascepa® (icosapent ethyl) t... GlobeNewswire Inc. - 3/28/2019 4:51:57 PM
New Updates to the American Diabetes Association’s® 2019 Standards of Medical Care in Diabetes Incorporate Findings from t... GlobeNewswire Inc. - 3/28/2019 5:00:00 AM
Cardiovascular Risk at Multiple Triglyceride Thresholds Highlighted in Presentation at American College of Cardiology’s 68... GlobeNewswire Inc. - 3/19/2019 6:00:00 AM
Additional Real-World Data Show a Significant Risk Increase in Cardiovascular Events in People with Elevated Triglyceride Lev... GlobeNewswire Inc. - 3/18/2019 4:15:00 PM
Vascepa® (icosapent ethyl) Showed 30% Reduction in Total Cardiovascular Events Including Recurrent Events in REDUCE-IT™ PR Newswire (US) - 3/18/2019 9:00:00 AM
High Risk of Atherosclerotic Cardiovascular Events Projected in People with Elevated Triglycerides Without Established Athero... GlobeNewswire Inc. - 3/16/2019 5:30:00 PM
Investor Expectations to Drive Momentum within Amarin, PulteGroup, LivaNova, Teva Pharmaceutical Industries, Viad, and Activi... GlobeNewswire Inc. - 3/6/2019 8:25:00 AM
Amarin to Present at Cowen’s 39th Annual Health Care Conference GlobeNewswire Inc. - 3/5/2019 6:00:00 AM
Important New Data on Vascepa® (Icosapent Ethyl) from the REDUCE-IT™ Trial to Be Presented Regarding Reduction in Total Is... GlobeNewswire Inc. - 3/4/2019 4:30:00 PM
Gibbs Law Group Has Filed Sole Class Action; Shareholders Should Contact the Firm About Their Rights Business Wire - 3/1/2019 5:00:00 PM
The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Amarin Corp. plc & En... Business Wire - 2/27/2019 2:25:00 PM
Annual Report (10-k) Edgar (US Regulatory) - 2/27/2019 6:39:33 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 2/27/2019 6:31:09 AM
Amarin Reports Record Fourth Quarter and Full Year 2018 Financial Results and Provides Update on Operations GlobeNewswire Inc. - 2/27/2019 5:00:00 AM
ilovetech   Tuesday, 02/12/19 11:43:30 AM
Re: BaaBaa45 post# 175770
Post # of 193532 
Baabaa45, I shared the warning letter with Amrn IR, which I encourage anyone to do when they find such gems, as you have here. Here is what she wrote back just now, sans my name:

Dear XXX- I don’t know if our legal group is aware of this particular letter so I forwarded to them.



As always- thank you! Our investor community is better at finding things than any web crawler. Please keep sending.



Warm Regards,

Elisabeth



Elisabeth Schwartz, Sr. Director of Investor Relations and Corporate Communications, Amarin Corporation plc

1430 Route 206, Bedminster, NJ 07921

Direct Number 908.326.2569 | Mobile 201.674.7876

Email: elisabeth.schwartz@amarincorp.com



Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (2) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist